S6.14.3 – Louise and Roger React to Empowered SLD Patient Advocates
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
October 9, 2025
After the roundtable, Louise Campbell and Roger Green share their reactions to the enthusiastic, empowered advocates who are the Harrison Fellows.
MASLD takes center stage in this week’s episode, exploring how alcohol, diet, and genetics shape disease outcomes and long-term mortality. From Swedish data on cause-specific deaths to personal stories of liver-focused care, the insights hit hard—and help chart a better path for patient health.
SLD Think Tank 2023 co-chairs Jörn Schattenberg and Jeff Lazarus and participants Maja Thiele and Mike Betel join Louise Campbell and Roger Green to discuss high points of the recent Barcelona meting.
Panelists reflecting on Stephen Harrison share what they consider his most important and lasting professional accomplishments.
This final conversation focuses on semaglutide and some of the dual- and triple-increting agonists and then reviews high points of the entire episode.
This conversation focuses on why it will be challenging to use currently-available NITs to stage patients with advanced MASH fibrosis (F2/F3) accurately with current test options.
From 2022: Chris Estes, then from the Center for Disease Analysis Foundation, and Alina Allen from the Mayo Clinic join the Surfers to discuss the creation of a 15-country epidemiology model for MASLD/NAFLD and MASH/NASH and what it tells us about the future path of the disease, and specifically treatment of advanced fibrosis.
Zobair Younossi and Louise Campbell lead a discussion that focuses first on slowing the growth of the MASLD pandemic, then on issues specific to menopausal women
Zobair Younossi discusses the disease burden of MASLD as characterized in his recent publication “Understanding the Burden of Fatty Liver Disease: Time for Action”
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.